Discussion
PPL is very rare, and its biological features, clinical presentation, prognostic markers, and treatment are not well defined. Although PPL has various clinical symptoms, they are nonspecific and contribute little to the diagnosis. Furthermore, 37.5-50% of patients are asymptomatic [
2],[
7]. Moreover, the rate of constitutional symptoms and acute-phase reactants (sedimentation, C-reactive protein) are high in patients with PPL, which is also not specific to the diagnosis [
8]. Thus, in addition to the pathological manifestations of bronchial mucosal biopsy and surgical biopsy, abnormal chest radiography and CT images may also be of value for diagnosis. Recently, increased numbers of disuse large B-cell lymphoma (DLBCL) cases with various manifestations have been reported, which could be misdiagnosed as TB [
9] or lung cancer [
10]. A long-term follow-up study of PPL-DLBCL, the largest known series thus far, noted strong homogeneity among the patients: low clinical risk, early stage, and no bulky tumor mass, normal lactic dehydrogenase and beta 2 microglobulin [
11]. Yet, some cases also have unusual morphological features, where primary pulmonary B cell lymphoma might present as a necrotic mass or mediastinal type [
12],[
13].
The most common histopathological subtypes of PPL are mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B cell lymphoma (DLBCL), which occurs only in 10% of cases [
14],[
15]. In general, there is no clear classification of DLBCL encountered in pulmonary systems. In fact, PLL-DLBCL has been reported only in case reports [
9],[
10], most subtypes of them are centroblastic or immunoblastic variants, as elsewhere, which are the more common morphological variants of DLBCL [
1],[
11],[
16],[
17]. In addition, some rare types of DLBCL, such as the anaplastic variant, were also reported [
18]. Histopathologically, the case we presented here contained both large and small lymphoid cells, and abundant eosinophils were also found in the tumor tissue. Immunohistochemical staining revealed that the large lymphoid cells were B-cells (both CD20- and Pax5-positive) and small lymphoid cells were predominantly T-cells (CD3-positive) in nature. Our finding is obviously different from the studies [
11],[
13],[
19] in which immunophenotype of primary B cell lymphoma of the lung is commonly CD3-negative. Meanwhile, many CD68-positive cells were also found, but there were only a few large CD30-positive and CD1α-positive cells in the tumor tissue. In addition, no any S100-positive and definite CD15-positive cells were found. It means that large B-cells are mingled with abundant small T-cells and histiocytes. BIOMED-2 gene rearrangement analysis [
6] of both the lung tissue and tumor cells confirmed that large B-cells are neoplastic and small T-cells are reactive. Therefore, the diagnosis of this case is T- cell/histiocyte-rich large B cell lymphoma (THRLBCL), which is a special and rare subtype of DLBCL. Based on the typical cellular and immunohistochemical features of THRLBCL, which is composed of the dispersed large B-cells, predominant small T-cells and more histiocytes, it is not difficult to differentially diagnose it from other large B-cell lymphoma. If there is a difficult case, laboratory evaluation for EBV [
20],[
21] and immunohistochemical staining of OCT2 and BOB1 [
22],[
23] may be useful for the differential diagnosis of THRLBCL with other large B-cell lymphoma.
Upon histopathological examination, a marked increase of eosinophils in non-blood tissue could be diagnosed as tissue eosinophilia. However, eosinophilia refers to increased eosinophils (>0.45 × 10
9/L) in the peripheral blood [
24]. Peripheral blood and tissue eosinophilia may occur in many disorders, including allergic and hypersensitivity diseases, parasitic and viral infections, atopic reactions, immune complex disorders, connective tissue diseases, and malignant tumors. Both solid tumors and hematopoietic neoplasms are associated with eosinophilia. Eosinophilia and tissue eosinophilia are frequent findings in Hodgkin lymphoma [
25] and are sometimes observed in patients with lymphoma, predominantly T cell lymphoma or occasionally anaplastic large cell lymphoma [
26],[
27]. Historically, large B cell lymphoma with marked eosinophilia is rare, and only a few cases of mediastinal/thymic large B cell lymphoma may present a few reactive infiltrating lymphocytes and eosinophils. Its clinical manifestation is an anterior mediastinal space-occupying lesion, usually accompanied by superior vena cava syndrome, and is easily misdiagnosed as Hodgkin lymphoma. To date, there are only a few reports on eosinophilia or tissue eosinophilia in B cell lymphoma, and all biopsy samples are obtained from lymph nodes [
28]-[
30]. In our case, however, it was primary pulmonary B cell lymphoma without evidence of nodal involvement, and all biopsy samples were obtained from lung tissue. The peripheral blood eosinophilic granulocyte count was in the normal range, and the bone marrow biopsy was normal. These findings did not support the diagnosis of eosinophilia. However, histopathological examination disclosed a lesion with marked eosinophil infiltration, some of which formed eosinophilic abscesses.
The differential diagnoses of eosinophil-rich lesions of the lung included eosinophilic granuloma, Hodgkin's lymphoma and parasitic or viral infections. In eosinophilic granuloma, there are a large number of characteristic Langerhans cells, which have typical nuclear grooves and showed both CD1α and S100 diffuse positive staining. Furthermore, the gene rearrangement analysis can not reveal the clonal rearrangement of IGH genes. In classical Hodgkin's lymphoma, there are the typical Reed-Sternberg cells and their variants. In addition, abundant CD30- and CD15- positive cells may be also helpful for differential diagnosis with a large B-cell lymphoma. In parasitic or viral infections, it would yield polypides, eggs, or viral inclusion bodies under microscopy. Taken together, eosinophilic granuloma, Hodgkin's lymphoma and parasitic or viral infections could be excluded respectively.
Based on the cellular, immunohistochemical and molecular findings, we think that this is a unique case of primary pulmonary large B cell lymphoma with tissue eosinophilia.
The mechanism clarifying the relationship between tissue eosinophilia and B cell lymphoma remains unknown. Typically, it is believed that the eosinophilia is caused by the production of various cytokines, such as interleukin (IL)-5, IL-3, and granulocyte-macrophage colony'stimulating factor (GM-CSF) by B cell lymphoma cells or non-neoplastic T lymphocytes activated by B cell lymphoma cells [
30],[
31]. In addition to the eosinophil chemotactic factors IL-3 and GM-CSF, IL-5 is a major soluble factor for mediating eosinophilia. It can be both a paracrine secretion from T cells [
32] and an autonomous autocrine secretion from activated eosinophils [
33],[
34]. Although the role of IL-4 in eosinophil recruitment is controversial [
31], IL-4 is highly expressed by T cytotoxic 2 cells, with abundant background eosinophils, in CD8
+ lymphomatoid papulosis [
35]. Generally, these secreted cytokines may either act locally, recruiting eosinophils to the neoplasm, or have a systematic effect, increasing the number of eosinophils maturing and leaving the bone marrow [
29]. Although the reason for tissue eosinophilia is as yet unknown, a large study of 1511 diagnostic biopsy specimens of patients has revealed that tissue eosinophilia correlated strongly with poor prognosis in nodular sclerosing Hodgkin's disease [
36]. Similarly, the prognosis of large B cell lymphoma with tissue eosinophilia remains unknown for the rare of such cases and should also be considered.
There is evidence that MALT lymphoma of the lung is a very indolent disease with the potential for spontaneous regression [
37] and that DLBCL of the lung may not portend as poor a prognosis as in other extranodal sites [
11]. Prompt pathological diagnosis and initiation of therapy, including surgery, chemotherapy, radiotherapy, or combined treatments, are crucial to patient outcome. To date, the most effective therapy is anthracycline-containing chemotherapy, such as the CHOP or CHOP-like regimen, which is more commonly offered. The long-term follow-up study of Neri et al. showed that patients treated with CHOP achieved complete response (CR) >80% and progression-free survival (PFS) and overall survival (OS) >5 years [
11]. Although the addition of rituximab to CHOP (R-CHOP) increased the CR rate, PFS, and OS in DLBCL [
38],[
39], especially in younger patients with low clinical risk, a recent study reported that there was no statistical difference in PPL-DLBCL following a retrospective comparison of patients who received R-CHOP or CHOP alone [
40].
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JZ selected the research topic, participated in the study, and wrote the manuscript. YMW carried out the immunoassays and wrote the manuscript. LG participated in the molecular genetic studies. GSH participated in the study design, contributed to the acquisition of clinical data and assisted the manuscript editing. All authors read and approved the final manuscript.